Kymera Therapeutics Inc
KYMR
Health Care
2
exclusion reasons
1 theme
Kymera Therapeutics Inc is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Kymera Therapeutics is a clinical-stage biopharmaceutical company whose core business model involves the development of novel protein degraders. The advancement of its drug candidates through preclinical and clinical stages inherently relies on animal testing to assess safety, efficacy, and toxicology. The company has publicly disclosed conducting non-GLP toxicology studies in animals, such as a 14-day oral administration study for one of its lead candidates, as a standard part of its development process. This places its operations within the scope of commercial animal exploitation for biomedical research and product testing.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies. Its pipeline candidates, including KT-474, KT-333, and KT-621, are progressing through clinical trials. As disclosed in SEC filings, securing regulatory approval for these novel drugs requires the submission of extensive preclinical data, which includes nonclinical laboratory and animal tests conducted in accordance with Good Laboratory Practices (GLPs). The company’s lease agreement for its laboratory space explicitly permits animal research. A specific non-GLP toxicology study of 14 days’ duration was cited in company materials as part of this development process. This places Kymera within the standard pharmaceutical industry practice of conducting animal testing to fulfill regulatory requirements for investigational new drug applications.
Research Sources
9 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.